全文获取类型
收费全文 | 10482篇 |
免费 | 494篇 |
国内免费 | 136篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 165篇 |
妇产科学 | 63篇 |
基础医学 | 1200篇 |
口腔科学 | 270篇 |
临床医学 | 688篇 |
内科学 | 2950篇 |
皮肤病学 | 147篇 |
神经病学 | 670篇 |
特种医学 | 438篇 |
外科学 | 2197篇 |
综合类 | 40篇 |
预防医学 | 222篇 |
眼科学 | 118篇 |
药学 | 574篇 |
中国医学 | 15篇 |
肿瘤学 | 1277篇 |
出版年
2023年 | 89篇 |
2022年 | 154篇 |
2021年 | 292篇 |
2020年 | 163篇 |
2019年 | 179篇 |
2018年 | 234篇 |
2017年 | 185篇 |
2016年 | 247篇 |
2015年 | 250篇 |
2014年 | 372篇 |
2013年 | 438篇 |
2012年 | 672篇 |
2011年 | 725篇 |
2010年 | 405篇 |
2009年 | 347篇 |
2008年 | 654篇 |
2007年 | 678篇 |
2006年 | 671篇 |
2005年 | 730篇 |
2004年 | 699篇 |
2003年 | 648篇 |
2002年 | 638篇 |
2001年 | 123篇 |
2000年 | 87篇 |
1999年 | 139篇 |
1998年 | 172篇 |
1997年 | 123篇 |
1996年 | 120篇 |
1995年 | 90篇 |
1994年 | 81篇 |
1993年 | 86篇 |
1992年 | 80篇 |
1991年 | 72篇 |
1990年 | 65篇 |
1989年 | 72篇 |
1988年 | 46篇 |
1987年 | 32篇 |
1986年 | 32篇 |
1985年 | 35篇 |
1984年 | 25篇 |
1983年 | 24篇 |
1982年 | 16篇 |
1981年 | 17篇 |
1980年 | 11篇 |
1979年 | 11篇 |
1978年 | 11篇 |
1975年 | 10篇 |
1973年 | 11篇 |
1971年 | 8篇 |
1970年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. 总被引:3,自引:0,他引:3
92.
93.
Fluorescence in situ Hybridization Analysis of 12;21 Translocation in Japanese Childhood Acute Lymphoblastic Leukemia 总被引:1,自引:0,他引:1
Minenori Eguchi-Ishimae Mariko Eguchi Kimio Tanaka Kazuko Hamamoto Misao Ohki Kazuhiro Ueda Nanao Kamada 《Cancer science》1998,89(7):783-788
Fluorescence in situ hybridization (FISH) analysis was applied to detect t(12;21) using two yeast artificial chromosome probes and cosmid probes covering the TEL(ETV6) and the AML1 gene to clarify the incidence of abnormality of t(12;21) in Japanese childhood acute lymphoblastic leukemia (ALL). We detected seven TEL/AML1 fusion positive patients (9.5%), all of whom were diagnosed as B-lineage ALL, among 74 childhood ALL. On the other hand, no TEL/AML1 fusion positive patients were found among 37 adult ALL. The incidence among Japanese seemed to be lower than that among other nations. Of the seven patients with the TEL/AML1 fusion, five exhibited normal karyotype, one was t(8;12)(q11;p13), i(21q) and the remaining one exhibited a near-triploid karyotype in conventional G-banding. The FISH method clearly demonstrated that all patients with the TEL/AML1 fusion had subpopulations of leukemic cells with deletion of the normal TEL allele, which is significant for understanding the progression of leukemia with t(12;21). 相似文献
94.
Taro Maeda Yukihiro Shintani Kanako Nakano Kazuhiro Terashima Yoshiyasu Yamada 《Pediatrics international》2004,46(2):122-125
BACKGROUND: The efficacy of inactivated influenza vaccine in healthy infants and children younger than 24 months has not been confirmed. The aim of the present study was to determine the prophylactic effect of inactivated influenza vaccine against influenza A in healthy children aged 6-24 months. METHODS: Healthy infants and young children (6-24 months old) were immunized by subcutaneous injection of inactivated influenza vaccine before influenza seasons. Age matched children were randomly assigned as the control. These children were followed up from January to April in each year (2000, 2001 and 2002). The attack rates of influenza A infection was compared and statistically assessed. RESULTS: The attack rate of influenza A virus infection in the vaccine group and the control group were 14.8% (n = 27) vs 12.5% (n = 32) in 2000 (P = 0.526); 2.8% (n = 72) vs 7.2% (n = 69) in 2001 (P = 0.203); and 3.4% (n = 52) vs 8.9% (n = 56) in 2002 (P = 0.205). The attack rates of influenza A between the two groups were not significantly different. CONCLUSIONS: Inactivated influenza vaccine did not reduce the attack rate of influenza A infection in 6-24 month old children. 相似文献
95.
Hashimoto T Goto K Hishinuma Y Yachuda K Sugioka Y Arai K Harada S Goto M 《Annals of nuclear medicine》2000,14(4):293-298
99mTc-tetrofosmin, Thallium-201-chloride (201Tl) and 99mTc-MIBI imagings were performed in a patient with malignant thymoma. Tracer uptake in the primary tumor was demonstrated. The tumor-to-background ratios of planar and SPECT imagings were 1.60 and 1.98 for 99mTc-tetrofosmin, 1.12 and 2.09 for 201Tl, and 1.19 and 1.80 for 99mTc-MIBI, respectively. In another patient 99mTc-tetrofosmin and 201Tl imagings were performed. Not only the primary tumor but also the direct invasions and metastatic lesions (bone metastases) were clearly detected. The tumor-to-background ratios of planar and SPECT imagings were 2.31 and 2.78 for 99mTc-tetrofosmin and 2.45 and 3.58 for 201Tl, respectively. In 99mTc-tetrofosmin scintigraphy we acquired delayed images, and the tumor-to-background ratios of planar and SPECT delayed images were 1.20 and 1.86, the retention ratios were -1.11 and -0.92 and the retention indices were -48.1 and -33.1, respectively. Our preliminary results suggest that 99mTc-tetrofosmin is useful in detecting not only the primary tumor but also metastatic lesions from malignant thymoma. 相似文献
96.
Nishiguchi S Shiomi S Sasaki N Iwata Y Tanaka H Kubo S Hirohashi K Ochi H 《Annals of nuclear medicine》2000,14(5):383-386
A 39-year-old woman with acute cholecystitis and gallstones underwent laparoscopic cholecystectomy. She suffered from recurrent episodes of cholangitis due to injury of the major bile ducts during laparoscopic cholecystectomy. Hepatobiliary scintigraphy with Tc-99m Sn-N-pyridoxyl-5-methyltryptophan was performed. Although normal bile excretion was found from the left hepatic duct to the percutaneous transhepatic biliary drainage (PTBD) tube, excretion from the right hepatic lobe was prolonged. Scintigraphy with Tc-99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin demonstrated atrophy of the right hepatic lobe and enlargement of the left hepatic lobe. Cholangiography via the PTBD tube revealed complete obstruction of the left hepatico-jejunal anastomosis and could not enhance the right intrahepatic bile duct. A right hepatic lobectomy was performed because of the atrophy, glissonitis and the absence of an appropriate bile duct for reconstruction. Postoperatively she was active and exhibited no evidence of recurrent cholangitis. 相似文献
97.
Tomohiro Komatsu Makoto Ayaori Harumi Uto-Kondo Katsumi Hayashi Katsumi Tamura Hiroki Sato Makoto Sasaki Takafumi Nishida Shunichi Takiguchi Emi Yakushiji Kazuhiro Nakaya Katsunori Ikewaki 《Journal of atherosclerosis and thrombosis》2022,29(5):775
Aims: Inflammation is involved in various processes of atherosclerosis development. Serum C-reactive protein (CRP) levels, a predictor for cardiovascular risk, are reportedly reduced by statins. However, several studies have demonstrated that CRP is a bystander during atherogenesis. While S100A12 has been focused on as an inflammatory molecule, it remains unclear whether statins affect circulating S100A12 levels. Here, we investigated whether atorvastatin treatment affected S100A12 and which biomarkers were correlated with changes in arterial inflammation. Methods: We performed a prospective, randomized open-labeled trial on whether atorvastatin affected arterial (carotid and thoracic aorta) inflammation using18fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and inflammatory markers. Thirty-one statin-naïve patients with carotid atherosclerotic plaques were randomized to either a group receiving dietary management (n=15) or one receiving atorvastatin (10mg/day,n=16) for 12weeks.18F-FDG-PET/CT and flow-mediated vasodilation (FMD) were performed, the latter to evaluate endothelial function. Results: Atorvastatin, but not the diet-only treatment, significantly reduced LDL-cholesterol (LDL-C, -43%), serum CRP (-37%) and S100A12 levels (-28%) and improved FMD (+38%).18F-FDG-PET/CT demonstrated that atorvastatin, but not the diet-only treatment, significantly reduced accumulation of18F-FDG in the carotid artery and thoracic aorta. A multivariate analysis revealed that reduction in CRP, S100A12, LDL-C, oxidized-LDL, and increase in FMD were significantly associated with reduced arterial inflammation in the thoracic aorta, but not in the carotid artery. Conclusions: Atorvastatin treatment reduced S100A12/CRP levels, and the changes in these circulating markers mirrored the improvement in arterial inflammation. Our observations suggest that S100A12 may be an emerging therapeutic target for atherosclerosis. 相似文献
98.
T‐cell‐rich HLA‐haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy 下载免费PDF全文
Hideki Sano Kazuhiro Mochizuki Mitsuko Akaihata Shogo Kobayashi Hitoshi Ohto Atsushi Kikuta 《Pediatric blood & cancer》2017,64(3)
Intensive chemotherapy with tyrosine kinase inhibitor (TKI) improves the prognosis of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐ALL). However, the prognosis of cases of relapsed or refractory Ph‐ALL remains poor. Here, we aimed to assess the efficacy of T‐cell‐rich HLA‐haploidentical hematopoietic stem cell transplantation (TCR‐haplo‐HSCT) in eight patients with relapsed or refractory pediatric Ph‐ALL. Transplant‐related mortality was observed in two patients. All patients discontinued TKI after receiving TCR‐haplo‐HSCT. The 3‐year probability of overall survival and event‐free survival was 75.0 and 62.5%, respectively. These results indicate the efficacy of TCR‐haplo‐HSCT for relapsed/refractory pediatric Ph‐ALL. 相似文献
99.
Katsumi Hirose Takahiro Kato Takaomi Harada Tomoaki Motoyanagi Hiroki Tanaka Akihiko Takeuchi Ryohei Kato Shinya Komori Yuhei Yamazaki Kazuhiro Arai Noriyuki Kadoya Mariko Sato Yoshihiro Takai 《Journal of radiation research》2022,63(4):620
The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT. 相似文献
100.
Kan Yonemori Yasutoshi Kuboki Kosei Hasegawa Takashi Iwata Hidenori Kato Kazuhiro Takehara Yasuyuki Hirashima Hisamori Kato Chaitali Passey Jeppe Klint Buchbjerg Jeffrey R. Harris Camilla
Mondrup Andreassen Leonardo Nicacio Ibrahima Soumaoro Keiichi Fujiwara 《Cancer science》2022,113(8):2788
New treatments, particularly second‐line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cytotoxic monomethyl auristatin E. This single‐arm, open‐label phase 1/2 trial evaluated the consistency of safety and efficacy outcomes of TV in Japanese patients with r/mCC to bridge the current findings with those reported in previous trials in non‐Japanese patients in the United States and Europe. In part 1 (dose escalation; N = 6), patients with advanced solid tumors received TV 1.5 or 2.0 mg/kg once every 3 weeks to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 (dose expansion; N = 17) evaluated the RP2D in r/mCC patients with 1–2 prior lines of therapy. In part 1, no dose‐limiting toxicities were observed, the MTD was not reached, and TV 2.0 mg/kg was established as the RP2D. In part 2, the most common treatment‐emergent adverse events were anemia (58.8%), nausea (58.8%), alopecia (47.1%), epistaxis (47.1%), and diarrhea (35.3%); adverse events of special interest were bleeding (76.5%), ocular events (35.3%), and peripheral neuropathy (17.6%), and were mostly grade 1/2. In part 2, confirmed objective response rate was 29.4%, median duration of response was 7.1 months, and median time to response was 1.2 months. In Japanese patients with r/mCC, TV demonstrated a manageable and tolerable safety, pharmacokinetics, and efficacy profile consistent with that observed in non‐Japanese patients. 相似文献